Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 16Cyclophosphamide 9Nivolumab 7atezolizumab 6fludarabine 5Specimen Handling 5Magnetic Resonance Spectroscopy 5cabozantinib 4Trastuzumab 4budigalimab 3Ipilimumab 3Interleukin-2 3Cisplatin 3Capecitabine 3Albumin-Bound Paclitaxel 3spartalizumab 2sargramostim 2poly ICLC 2palbociclib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2X-Rays 2Sunitinib 2Paclitaxel 2Irinotecan 2Interleukin-12 2Immunoglobulin G 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × tomivosertib × Breast × Clear all
NCT03318562 2019-07-18

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Effector Therapeutics

Phase 2 Terminated
3 enrolled
BreastGastrointestinal

Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡